Evaluation of safety and efficacy of Desferal + Zinc nasal spray
Phase 2
Recruiting
- Conditions
- covid19.COVID19, virus identifiedU07.1
- Registration Number
- IRCT20210519051348N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Informed and written consent of patient with Coronavirus Confirmation disease by clinical and laboratory signs Serum creatinine less than two Milligram per Deciliter Absence of heart problems( myocarditis- heart failure ) Hemoglobin above 8 Gram per Deciliter Patients admitted to the ward with moderate symptoms 18 to 65 years
Exclusion Criteria
Ferritin lower than 100 milligram per deciliter Diabetes History of blood coagulation problems Pregnancy and Breastfeeding History of neurologic problems History of vision and hearing problems concomitant use of vitamin C Intubated patient History of Desferal or Zinc allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Interleukin6. Timepoint: Before and after the intervention. Method of measurement: ELISA KIT.;Body temperature. Timepoint: Before the intervention and every day during the study. Method of measurement: Thermometer.;Oxygen saturation. Timepoint: Before the intervention and every day during the study. Method of measurement: Pulse oximeter.;Cough. Timepoint: Before the intervention and every day during the study. Method of measurement: questionnaire.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: Admission period until hospital discharge. Method of measurement: Patient file.;Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire.